[1] |
ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan.
Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
|
[2] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[3] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[4] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[5] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[6] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[7] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[8] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[9] |
DENG Yurong, SUN Jianhui, HAO Liyu, SHAN Zhongchao, YU Zeyue, LI Jianliang, HUO Hairu, LI Qijing, ZHANG Hongmeng, LI Hongmei.
Therapeutic effect and mechanism of Bairui granules against influenza virus-induced viral pneumonia in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1249-1255.
|
[10] |
LIU Bin, SHAO Meiling, CAI Yiran, MA Fengyi, LAN Hong.
Applicability of PDCA cycle in standardization of outpatient prescriptions
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1035-1039.
|
[11] |
MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao.
Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.
|
[12] |
LI Xiaofei, CHENG Rong, WU Xuemei, LIU Zhi.
Safety of terlipressin for injection based on electronic medical records
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 654-656.
|
[13] |
CHEN Fangfang, ZHANG Hongxu.
Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.
|
[14] |
JIN Haobin, ZHENG Lei, YANG Jing, GUAN Yuyao, ZHANG Xiaoli.
Adverse reactions of skin drugs and concomitant liver and kidney dysfunction in inpatients
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 310-312.
|
[15] |
LYU Juan, GUO Weiyan, WANG Yuanji, LI Yamei, WANG Yingli, DUAN Shiwan.
115 cases of drug-related adverse reactions in the liver
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 200-204.
|